The ban on the Ranbaxy factory is the latest blow for India’s generics industry, which sells drugs and ingredients worldwide. Products from three other Ranbaxy plants were already prohibited in the U.S. because of quality control issues, while other local competitors such as Wockhardt Ltd. (WPL) have also come under scrutiny from the FDA.
This is now becoming a regular feature with the Indian generic drug manufacturers from India. If they do this for drugs going to the US market, then I wonder what standards do drug manufacturers maintain for drugs sold in Indian markets. Has any one thought of that.?